Fig. 7.

Systemic E260 treatment attenuates CC xenograft progression in immuno-compromised mice. a PK analysis of E260 in mice blood following IP administration of the compound; n = 5 for each time point. b Summary table for E260 PK parameters and distribution in vivo. c Tumor progression in mice bearing SW620 derived xenografts fed with restricted diet and injected IP twice a day with control vehicle, 25 mg/kg E260, or 50 mg/kg E260; n = 8, ±SE. d Average tumor volume after 22 days of treatment: control (blue), 25 mg/kg E260 (yellow), and 50 mg/kg E260 (red); n = 8, ±SE. e–g Representative images of mice bearing SW620 xenografts at day 22 post injection. h Tumor progression in mice bearing SW620 derived xenografts fed with ad libitum diet and injected IP twice a day with vehicle or 50 mg/kg E260; n = 8, ±SE. i Average tumor volume after 22 days of treatment with vehicle (blue) or 50 mg/kg E260 (red); n = 8, ±SE. j progression in mice bearing SW48 xenografts and injected IP twice a day with vehicle, 25 mg/kg E260, or 50 mg/kg E260; n = 8, ±SE. k Average tumors volume after 22 days of treatment: control (blue), 25 mg/kg E260 (yellow) and 50 mg/kg E260 (red); n = 8, ±SE. l–n Representative images of mice bearing SW48 xenografts at day 22 post injection. o–t Representative images of tumor sections dissected from mice at day 22 of treatment with control (vehicle only) (o, r), 25 mg/kg E260 (p, s), or 50 mg/kg E260 (q, t). Bars represent 200 µm. u, w Weight profiles of mice bearing SW620 (u) or SW48 (w) xenografts and IP injected twice a day with control, 25 mg/kg E260, or 50 mg/kg E260; n = 8, ±SE. v, x Average starting weights and end-point weights of mice bearing tumors derived from SW620 (v) or SW48 (x) cells after 22 days of twice daily IP injection: control, 50 mg/kg E260, or 25 mg/kg E260; n = 8, ±SE